Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now.

On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) to $7 from $12 and maintained an Outperform rating. Evercore ISI said the adjustment reflects updates across its small-to-mid cap biotechnology coverage as it reviewed Q2 catalysts, while noting stocks in the group are trading more on longer-horizon theses and broader FY26 catalysts.

On March 31, 2026, CEO Jeet Mahal said briquilimab has a “compelling and differentiated profile” in CSU and CIndU, with proof of concept in asthma, highlighting data from the BEACON study and open-label extension showing rapid and durable disease control. Jeet Mahal added that the company is finalizing dose selection for a Phase 2b/3 study in CSU and expects to begin patient enrollment in the second half of 2026, pending capital availability.

Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7

Photo from Iovance Biotherapeutics website

On March 23, 2026, UBS initiated coverage on Jasper Therapeutics with a Neutral rating and a $1.50 price target. UBS said the stock presents a balanced risk-reward over the next 12 months, citing competitive uncertainties while noting dose optimization data could provide upside.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) develops therapeutics targeting mast and hematopoietic stem cell-driven diseases.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.